Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Programmed cell death ligand 1 (PD-L1) is a transmembrane protein that inhibits anti-tumor immune responses.
• PD-L1 targeted therapies show promise in various cancers, but its role in osteosarcoma is unclear.
• Understanding PD-L1's function is crucial for developing new osteosarcoma treatments.

Purpose of the Study:

• To investigate the expression and prognostic significance of PD-L1 in osteosarcoma.
• To explore the therapeutic potential of targeting PD-L1 using CRISPR/Cas9 gene editing in osteosarcoma.

Main Methods:

• Immunohistochemistry on osteosarcoma tissue microarrays to assess PD-L1 expression.
• CRISPR/Cas9 gene editing to knock out the PD-L1 gene in osteosarcoma cell lines.
• Evaluation of drug sensitivity to doxorubicin and paclitaxel following PD-L1 knockdown.

Main Results:

• PD-L1 protein is expressed in osteosarcoma cell lines and patient tumors.
• High PD-L1 expression correlates with significantly shorter overall and five-year survival rates.
• High PD-L1 levels are associated with increased metastasis in osteosarcoma patients.
• CRISPR/Cas9 efficiently disrupted PD-L1 expression, enhancing sensitivity to doxorubicin and paclitaxel.

Conclusions:

• PD-L1 serves as an independent prognostic factor in osteosarcoma.
• PD-L1 knockout via CRISPR/Cas9 presents a potential therapeutic strategy for osteosarcoma treatment.
• Targeting PD-L1 may improve the efficacy of existing chemotherapies in osteosarcoma.